All Stories

  1. Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics
  3. Structure-Based Prediction of Anti-infective Drug Concentrations in the Human Lung Epithelial Lining Fluid
  4. Mechanistic models enable the rational use ofin vitrodrug-target binding kinetics for better drug effects in patients
  5. Prediction of long-term treatment outcome in HCV following 24 day PEG-IFN alpha-2b therapy using population pharmacokinetic-pharmacodynamic mixture modeling and classification analysis
  6. Towards integrative systems pharmacology models in oncology drug development
  7. Topics in Mathematical Pharmacology
  8. Sensitivity of pharmacokinetic–pharmacodynamic analysis for detecting small magnitudes of QTc prolongation in preclinical safety testing
  9. Drug Disposition in Obesity: Toward Evidence-Based Dosing
  10. Translating the gap in the evaluation of drug-induced QTc-interval prolongation from in vivo to the clinic
  11. The rise of systems pharmacology in drug discovery and development
  12. Pharmacometrics in Cardiovascular Safety
  13. Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point
  14. A4S: A user-friendly graphical tool for pharmacokinetic and pharmacodynamic (PK/PD) simulation
  15. A mathematical model of the human menstrual cycle for the administration of GnRH analogues
  16. Cross-membrane signal transduction of receptor tyrosine kinases (RTKs): from systems biology to systems pharmacology
  17. CPT: Pharmacometrics and Systems Pharmacology
  18. Mechanism-based PK–PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans
  19. Biomarkers and biomeasures: key enablers for pharmacokinetic–pharmacodynamic modeling in drug discovery and development
  20. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival
  21. Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C
  22. Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo
  23. Translation of drug-induced QTc prolongation in early drug development
  24. Mathematical analysis of the pharmacokinetic–pharmacodynamic (PKPD) behaviour of monoclonal antibodies: Predicting in vivo potency
  25. Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development
  26. Pharmacokinetic–pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys
  27. Pharmacodynamic-Pharmacokinetic Integration as a Guide to Medicinal Chemistry
  28. Cardiovascular profiles of beta3 agonists
  29. PK/PD Modelling: Validation and use of iterative development of experimental designs
  30. Impact of protein binding on receptor occupancy: A two-compartment model
  31. ChemInform Abstract: Synthesis and Use of FSCPX, an Irreversible Adenosine A1 Antagonist, as a “Receptor Knock-Down” Tool.
  32. Online solid phase extraction with liquid chromatography–tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples
  33. Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent
  34. Estimation of binding rate constants using a simultaneous mixed-effects method: application to monoamine transporter reuptake inhibitor reboxetine
  35. Optimising in vivo pharmacology studies—Practical PKPD considerations
  36. Pharmacokinetic–pharmacodynamic reasoning in drug discovery and early development
  37. Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling
  38. Impact of plasma-protein binding on receptor occupancy: An analytical description
  39. A non-parametric method to analyse time-course of effect in the absence of pharmacokinetic data: Application to inhaled bronchodilators
  40. The role of mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) modelling in translational research of biologics
  42. Allometric Scaling of Pharmacodynamic Responses: Application to 5-Ht1A Receptor Mediated Responses from Rat to Man
  43. Current methods used to investigate G protein coupled receptor oligomerisation
  44. Novel Selective Inhibitors of Neutral Endopeptidase for the Treatment of Female Sexual Arousal Disorder. Synthesis and Activity of Functionalized Glutaramides
  45. Correlation between affinity and efficacy
  46. Modulation of agonist responses at the A1 adenosine receptor by an irreversible antagonist, receptor–G protein uncoupling and by the G protein activation state
  47. Pharmacokinetic–pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinoxan
  48. Synthesis and use of FSCPX, an irreversible adenosine A1 antagonist, as a ‘Receptor Knock-Down’ tool
  49. High-performance liquid chromatography of the neuroactive steroids alphaxalone and pregnanolone in plasma using dansyl hydrazine as fluorescent label: application to a pharmacokinetic-pharmacodynamic study in rats
  50. Enantioselective high-performance liquid chromatographic analysis of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin
  51. Estimation of agonist affinity, using the slope of the concentration-effect curve: comment on the method of Calderone and Martinotti